Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelcitoclax plus Paclitaxel in Relapsed/Refractory SCLC
NCT04210037Phase 2Terminated
- Sponsor
- Ascentage Pharma
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of pelcitoclax in small cell lung cancer (SCLC) (3 arms), sponsored by Ascentage Pharma. Primary endpoints: Dose-Limiting Toxicity at 21 days and Objective Response Rate at 12 months. Started Aug 2020; status: terminated.
02
Drugs
pelcitoclax
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04210037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210037.